• Abbott's first-of-its-kind i2i™ technology enables synchronized communication between two leadless pacemakers
• The AVEIR™ DR leadless pacemaker system is roughly one-tenth the size of a traditional pacemaker and smaller than a AAA battery
• AVEIR DR leadless pacemakers are designed to address the needs of people in Europe living with abnormal heart rhythms and expand treatment options for Europeans

ABBOTT PARK, Ill., June 6, 2024 ­­­­— Abbott today announced it has received CE Mark in Europe for the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. Approximately 49 million people are living with cardiovascular disease in the European Union, and it is estimated that 14.4 million people 65 and older will have atrial fibrillation by 2060.^{1 2}  AVEIR DR is a breakthrough innovation that enables the world's first beat-to-beat, wireless communication between two leadless pacemakers, designed to address the needs of people living with abnormal heart rhythms and expand treatment options in Europe.